Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/12415| Title: | Myostatin inhibition: a new treatment for androgen deprivation-induced sarcopenia? | Austin Authors: | Grossmann, Mathis | Affiliation: | Department of Medicine Austin Health, University of Melbourne, and Endocrine Unit, Austin Health, Heidelberg, Victoria 3052, Australia | Issue Date: | 1-Oct-2014 | Publication information: | The Journal of Clinical Endocrinology and Metabolism; 99(10): 3625-8 | Gov't Doc #: | 25279574 | URI: | https://ahro.austin.org.au/austinjspui/handle/1/12415 | DOI: | 10.1210/jc.2014-3290 | Journal: | The Journal of Clinical Endocrinology and Metabolism | URL: | https://pubmed.ncbi.nlm.nih.gov/25279574 | Type: | Journal Article | Subjects: | Androgen Antagonists.adverse effects Body Mass Index Humans Immunoglobulin Fc Fragments.adverse effects Male Muscle, Skeletal.drug effects Myostatin.antagonists & inhibitors Prostatic Neoplasms.drug therapy Recombinant Fusion Proteins.adverse effects |
| Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.